Contract development and manufacturing organizations (CDMOs) are more critical than ever to the biopharmaceutical industry, providing essential outsourcing services to customers and helping them to focus on their core strengths. With fewer biopharma companies performing all of their manufacturing in-house, CDMOs provide much-needed, at-scale production capacity, as well as outsourced services such as drug development and testing to reduce costs and tap outside expertise.
This eHandbook takes a look at four CDMOs with global footprints that are positioned for growth in their respective markets and are redefining what it means to outsource.
Sponsored by: Colbert Packaging Corporation and Stirling Ultracold
